Oligonucleotide Synthesis Market
完整報告名稱與涵蓋範圍
Oligonucleotide Synthesis Market by Offering [Synthesis Products (Consumables, Equipment), Synthesized Oligos (DNA, RNA), Oligo-based Drugs (ASO, siRNA), Therapy Area [Rare Diseases, Neurology, Oncology], Competition - Global Forecast to 2031
報告摘要
The oligonucleotide synthesis market is projected to reach USD 32.72 billion by 2031, up from USD 14.64 billion in 2026, at a CAGR of 17.4% over the forecast period. Market growth is driven by several factors, including increasing demand for synthesized oligonucleotides such as primers and probes for research and diagnostic applications. Rising technological advancements in oligonucleotide synthesis are also expected to contribute to market growth during the forecast period.
By offering, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2025.
The market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides and oligonucleotide synthesis products (consumables and equipment). In 2025, the oligonucleotide-based drugs segment accounted for the largest share of the market. This large share reflects growing acceptance of these treatments and their proven success, especially for rare and hereditary diseases. Medications such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target disease-causing genes, providing precise and personalized treatments. This growing demand is fueled by advancements in RNA-targeted therapies and delivery systems, the rising prevalence of genetic diseases, and significant investments in research and development of RNA-based treatments.
In 2025, North America accounted for the largest share of the overall oligonucleotide synthesis market.
The US is the largest market for oligonucleotide synthesis, driving North America's commanding share of global market revenue. This dominance is propelled by a dense ecosystem of major biopharmaceutical companies, world-class academic research institutes, and extensive venture capital investment in genomic innovation. Furthermore, a massive clinical drug pipeline featuring over 150 oligo-based therapeutics, coupled with clear, supportive regulatory frameworks from the US FDA, drives demand for complex, large-scale, high-purity GMP production at a level unmatched by any other nation.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: C-level Executives - 30%, Directors- 45%, and Others- 25%
• By Region: North America - 35%, Europe - 25%, Asia Pacific - 15%, Latin America - 10%, Middle East- 10%, and Africa - 5%
Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US) are some of the key companies profiled in the report offering oligonucleotide synthesis products and synthesized oligonucleotides.
Biogen (US) Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland) are some of the key companies offering oligonucleotide-based drugs, profiled in the report.
Research Coverage:
This research report categorizes oligonucleotide synthesis market by offering (oligonucleotide-based drugs, synthesized oligonucleotides, oligonucleotide synthesis products); oligonucleotide-based drugs (by type: antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, other oligonucleotide-based drugs; by therapeutic area: rare diseases, cardiometabolic diseases, neurology, other therapeutic areas; by end user: hospitals, specialty clinics, home care settings, other end users); synthesized oligonucleotides (by oligo type: primers, probes, DNA oligos, RNA oligos, other oligos; by application: therapeutic applications, research applications, and diagnostic applications, by end user: biopharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and diagnostic companies & laboratories); oligonucleotide synthesis products (by type: consumables, oligo synthesis equipment; by application: therapeutic applications, research applications, and diagnostic applications, by end user: biopharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and diagnostic companies & laboratories), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report's scope covers detailed information on the primary factors, such as drivers, restraints, challenges, and opportunities, that influence the growth of the oligonucleotide synthesis market. A thorough analysis of key industry players has been conducted to provide insights into their business overviews, product offerings, key strategies, new product launches, acquisitions, and recent developments associated with the oligonucleotide synthesis market. This report also covers the competitive analysis of upcoming startups in the oligonucleotide synthesis market ecosystem.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of revenue for the oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following:
• Analysis of key drivers (Increasing use of synthesized oligos in therapeutic and diagnostic applications, technological advancements in oligonucleotide synthesis, growing government investments in life science research & synthetic biology, and growing focus on personalized medicine), restraints (Complexities associated with oligonucleotide-based drugs), opportunities (Increasing R&D investments by key players in emerging economies), and challenges (Lack of standard regulations, challenges in targeted delivery of oligonucleotides) are influencing the growth of the oligonucleotide synthesis market.
• Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market
• Market Development: Comprehensive information about lucrative markets – the report analyzes the oligonucleotide synthesis market across varied regions
• Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market
• Pipeline Analysis: Comprehensive information about oligonucleotide-based drugs under clinical trials
• Competitive Assessment: In-depth assessment of market, growth strategies, and product offerings of leading players, including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Merck KGaA (Germany), among others, offering oligonucleotide synthesis products and synthesized oligonucleotides. Biogen (US), Alnylam Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), and Sarepta Therapeutics, Inc. (US) are key players in the oligonucleotide-based drugs segment of this market.
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
目錄 Table of Contents
1 INTRODUCTION 63
1.1 STUDY OBJECTIVES 63
1.2 MARKET DEFINITION 64
1.3 STUDY SCOPE 64
1.3.1 MARKET SEGMENTATION & REGIONS COVERED 65
1.3.2 REGIONS COVERED 66
1.3.3 INCLUSIONS & EXCLUSIONS 66
1.3.4 YEARS CONSIDERED 68
1.3.5 CURRENCY CONSIDERED 68
1.4 STAKEHOLDERS 68
1.5 SUMMARY OF CHANGES 69
2 EXECUTIVE SUMMARY 70
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 70
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 72
2.3 DISRUPTIVE TRENDS IN OLIGONUCLEOTIDE SYNTHESIS MARKET 74
2.4 HIGH-GROWTH SEGMENTS 75
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 76
3 PREMIUM INSIGHTS 78
3.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 78
3.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET,
BY OFFERING AND COUNTRY, 2025 79
3.3 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 80
3.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY OFFERING, 2026 VS. 2031 (%) 81
4 MARKET OVERVIEW 82
4.1 INTRODUCTION 82
4.2 MARKET DYNAMICS 82
4.2.1 DRIVERS 83
4.2.1.1 Rising commercialization and regulatory approvals of oligonucleotide therapeutics 83
4.2.1.2 Expanding RNA therapeutics pipeline and adoption of chemically modified oligos 84
4.2.1.3 Growing use of PCR, qPCR, NGS, CRISPR, synthetic biology, and molecular diagnostics 85
4.2.1.4 Increasing outsourcing of oligonucleotide synthesis and GMP manufacturing to CROs/CDMOs 85
4.2.2 RESTRAINTS 86
4.2.2.1 Complexity of large-scale oligonucleotide manufacturing and analytical control 86
4.2.3 OPPORTUNITIES 86
4.2.3.1 Increasing government and industry investments in life sciences, RNA therapeutics, and manufacturing infrastructure 86
4.2.3.2 Expansion of oligonucleotide therapeutics into cardiometabolic and common chronic diseases 88
4.2.3.3 Growth of companion diagnostics and precision medicine 88
4.2.4 CHALLENGES 89
4.2.4.1 Lack of standard regulations 89
4.2.4.2 Delivery of oligonucleotide drugs to specific targets 89
4.2.4.3 Sustainability & waste management in phosphoramidite-based synthesis 90
4.3 UNMET NEEDS & WHITE SPACES 90
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 90
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 91
4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN THE OLIGONUCLEOTIDE-BASED DRUGS MARKET 91
4.5.2 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET 92
5 INDUSTRY TRENDS 93
5.1 PORTER’S FIVE FORCES ANALYSIS 93
5.1.1 OLIGONUCLEOTIDE-BASED DRUGS 93
5.1.1.1 Threat of new entrants 94
5.1.1.2 Threat of substitutes 94
5.1.1.3 Bargaining power of buyers 94
5.1.1.4 Bargaining power of suppliers 94
5.1.1.5 Intensity of competitive rivalry 94
5.1.2 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE
SYNTHESIS PRODUCTS 95
5.1.2.1 Threat of new entrants 96
5.1.2.2 Threat of substitutes 96
5.1.2.3 Bargaining power of buyers 96
5.1.2.4 Bargaining power of suppliers 96
5.1.2.5 Intensity of competitive rivalry 96
5.2 MACROECONOMIC OUTLOOK 97
5.2.1 INTRODUCTION 97
5.2.2 GDP TRENDS & FORECAST 97
5.2.3 TRENDS IN GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET 98
5.3 VALUE CHAIN ANALYSIS 98
5.4 ECOSYSTEM ANALYSIS 100
5.5 PRICING ANALYSIS 101
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY KEY PLAYER,
2022–2025 102
5.5.2 AVERAGE SELLING PRICE OF EQUIPMENT, BY REGION, 2025 104
5.6 KEY CONFERENCES & EVENTS, 2026–2027 105
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 105
5.8 INVESTMENT & FUNDING ACTIVITY 107
5.9 IMPACT OF 2025 US TARIFFS ON OLIGONUCLEOTIDE SYNTHESIS MARKET 108
5.9.1 INTRODUCTION 108
5.9.2 KEY TARIFF RATES 108
5.9.3 PRICE IMPACT ANALYSIS 109
5.9.4 IMPACT ON COUNTRY/REGION 110
5.9.4.1 North America 110
5.9.4.2 Europe 110
5.9.4.3 Asia Pacific 111
5.9.5 IMPACT ON END-USE INDUSTRIES 111
5.9.5.1 Hospitals 111
5.9.5.2 Specialty clinics 112
5.9.5.3 Home care settings & other end users 112
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 113
6.1 TECHNOLOGY ANALYSIS 113
6.1.1 KEY TECHNOLOGIES 113
6.1.1.1 Solid-phase phosphoramidite synthesis and scale-up 113
6.1.1.2 Liquid-phase synthesis 113
6.1.1.3 Chemical modification & backbone engineering 114
6.1.1.4 Conjugation & targeted delivery chemistry 114
6.1.1.5 Enzymatic & novel synthesis technologies 114
6.1.1.6 High-throughput automated oligonucleotide synthesis 114
6.1.1.7 Purification & analytical characterization 115
6.1.2 ADJACENT TECHNOLOGIES 115
6.1.2.1 Molecular biology & genomic technologies 115
6.1.2.2 Synthetic biology & gene synthesis 115
6.1.3 COMPLEMENTARY TECHNOLOGIES 116
6.1.3.1 Advanced oligonucleotide delivery technologies 116
6.1.3.2 AI-assisted oligonucleotide design 116
6.2 TECHNOLOGY/PRODUCT ROADMAP 116
6.3 FUTURE APPLICATIONS 117
6.4 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET 117
6.4.1 TOP USE CASES & MARKET POTENTIAL 118
6.4.2 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 119
6.4.3 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN OLIGONUCLEOTIDE SYNTHESIS MARKET 119
6.5 PATENT ANALYSIS & INNOVATIONS 120
6.5.1 OLIGONUCLEOTIDE SYNTHESIS MARKET: PATENT ANALYSIS, 2015–2025 121
6.5.2 KEY INNOVATIONS 122
7 SUSTAINABILITY & REGULATORY LANDSCAPE 123
7.1 REGIONAL REGULATIONS & COMPLIANCE 123
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 123
7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT 126
7.1.2.1 North America 126
7.1.2.2 Europe 126
7.1.2.3 Asia Pacific 126
7.1.2.4 Rest of the World 126
7.1.3 INDUSTRY STANDARDS 127
7.2 REIMBURSEMENT SCENARIO 127
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 130
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 130
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 132
8.1 DECISION-MAKING PROCESS 132
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 132
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 132
8.2.2 KEY BUYING CRITERIA, BY END USER 133
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 134
8.4 UNMET NEEDS FROM END USERS 135
8.5 MARKET PROFITABILITY 135
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING 136
9.1 INTRODUCTION 137
9.2 OLIGONUCLEOTIDE-BASED DRUGS 137
9.2.1 RECURRING CONSUMABLES DEMAND, AUTOMATION UPGRADES, AND ADVANCED SCREENING PLATFORMS TO DRIVE GROWTH 137
9.3 SYNTHESIZED OLIGONUCLEOTIDES 142
9.3.1 GROWING ADOPTION OF PCR, QPCR, NGS, AND CRISPR-BASED GENOME EDITING TO GENERATE SUBSTANTIAL DEMAND FOR CUSTOM PRIMERS 142
9.4 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS 145
9.4.1 INCREASING INSTALLATION OF AUTOMATED OLIGONUCLEOTIDE SYNTHESIZERS TO SUPPORT MARKET GROWTH 145
10 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE 149
10.1 INTRODUCTION 150
10.2 ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS 150
10.2.1 ASO-BASED DRUGS ACCOUNTED FOR LARGEST MARKET SHARE DUE TO THEIR ESTABLISHED CLINICAL SUCCESS ACROSS RARE AND
NEUROLOGICAL DISEASES 150
10.3 SIRNA OLIGONUCLEOTIDE-BASED DRUGS 155
10.3.1 EXPANDING COMMERCIAL ADOPTION AND STRONG LATE-STAGE PIPELINES TO DRIVE GROWTH 155
10.4 OTHER OLIGONUCLEOTIDE-BASED DRUGS 159
11 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA 164
11.1 INTRODUCTION 165
11.2 RARE DISEASES 165
11.2.1 GROWING APPROVALS FOR ORPHAN DISEASES TO MAKE RARE DISEASES LARGEST THERAPEUTIC AREA FOR OLIGONUCLEOTIDE THERAPEUTICS 165
11.3 NEUROLOGICAL DISORDERS 169
11.3.1 COMMERCIAL SUCCESS OF RNA-TARGETED THERAPIES TO CONTINUE TO STRENGTHEN NEUROLOGY SEGMENT 169
11.4 CARDIOMETABOLIC DISEASES 173
11.4.1 EXPANDING RNA THERAPEUTICS FOR CARDIOVASCULAR DISEASES TO MAKE CARDIOMETABOLIC DISEASES FASTEST-GROWING THERAPEUTIC AREA 173
11.5 OTHER THERAPEUTIC AREAS 177
12 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER 180
12.1 INTRODUCTION 181
12.2 SPECIALTY CLINICS 181
12.2.1 GROWING NETWORK OF SPECIALIZED RARE DISEASE TREATMENT CENTERS TO MAINTAIN SPECIALTY CLINICS AS LARGEST END-USER SEGMENT 181
12.3 HOSPITALS 185
12.3.1 COMPLEX PATIENT MANAGEMENT AND ADMINISTRATION OF ADVANCED OLIGONUCLEOTIDE THERAPIES TO CONTINUE TO SUPPORT HOSPITAL DEMAND 185
12.4 HOME CARE SETTINGS 189
12.4.1 SHIFT TOWARD CONVENIENT DOSING AND SELF-ADMINISTRATION TO MAKE HOME CARE SETTINGS FASTEST-GROWING END-USER SEGMENT 189
12.5 OTHER END USERS 193
13 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE 198
13.1 INTRODUCTION 199
13.2 PRIMERS 199
13.2.1 WIDESPREAD USE OF PRIMERS ACROSS RESEARCH, DIAGNOSTICS, AND THERAPEUTIC DEVELOPMENT TO FUEL GROWTH 199
13.3 PROBES 203
13.3.1 EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO DRIVE STRONG DEMAND FOR PROBES 203
13.4 DNA OLIGONUCLEOTIDES 206
13.4.1 BROAD APPLICABILITY ACROSS LIFE SCIENCE RESEARCH AND DIAGNOSTICS TO DRIVE SIGNIFICANT MARKET SHARE FOR DNA OLIGOS 206
13.5 RNA OLIGONUCLEOTIDES 210
13.5.1 RAPID GROWTH OF RNA THERAPEUTICS AND GENE-EDITING TECHNOLOGIES TO DRIVE MARKET MOMENTUM FOR RNA OLIGOS 210
13.6 OTHER OLIGONUCLEOTIDES 213
14 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE 217
14.1 INTRODUCTION 218
14.2 CUSTOM OLIGONUCLEOTIDES 218
14.2.1 RAPID CLINICAL AND COMMERCIAL EXPANSION OF CHEMICALLY MODIFIED ANTISENSE AND SIRNA THERAPEUTICS TO MAKE CUSTOM OLIGONUCLEOTIDES FASTEST-GROWING SEGMENT 218
14.3 PREDESIGNED OLIGONUCLEOTIDES 222
14.3.1 PREDESIGNED OLIGONUCLEOTIDES CONTINUE TO WITNESS STEADY DEMAND OWING TO WIDESPREAD USE IN ROUTINE RESEARCH AND MOLECULAR DIAGNOSTICS 222
15 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION 226
15.1 INTRODUCTION 227
15.2 RESEARCH APPLICATIONS 227
15.2.1 PCR 231
15.2.1.1 Widespread adoption of PCR across life science research to drive market growth 231
15.2.2 NGS 235
15.2.2.1 Sequencing to continue to expand with increasing adoption of next-generation sequencing technologies 235
15.2.3 OTHER RESEARCH APPLICATIONS 238
15.3 THERAEPUTIC DEVELOPMENT 241
15.3.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO SUPPORT GROWTH OF MARKET FOR THERAPEUTIC DEVELOPMENT APPLICATIONS 241
15.4 DIAGNOSTIC APPLICATIONS 244
15.4.1 INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO EXPAND MARKET FOR DIAGNOSTIC APPLICATIONS 244
16 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER 248
16.1 INTRODUCTION 249
16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 249
16.2.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO MAKE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES LARGEST END-USER SEGMENT 249
16.3 CROS & CDMOS 253
16.3.1 INCREASING OUTSOURCING OF OLIGONUCLEOTIDE DRUG DEVELOPMENT TO DRIVE FASTEST GROWTH AMONG CROS & CDMOS 253
16.4 DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES 256
16.4.1 GROWING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO DRIVE DEMAND 256
16.5 ACADEMIC & RESEARCH INSTITUTES 260
16.5.1 EXPANDING GENOMICS AND LIFE SCIENCE RESEARCH TO SUSTAIN DEMAND FROM ACADEMIC & RESEARCH INSTITUTES 260
17 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE 264
17.1 INTRODUCTION 265
17.2 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES 265
17.2.1 OLIGONUCLEOTIDE SYNTHESIS REAGENTS 270
17.2.1.1 Phosphoramidite building blocks 274
17.2.1.1.1 DNA phosphoramidites 278
17.2.1.1.1.1 Steady, high-volume primer, probe, and gene-synthesis demand to anchor DNA phosphoramidites as largest phosphoramidite revenue category 278
17.2.1.1.2 RNA phosphoramidites 282
17.2.1.1.2.1 Expansion of siRNA and CRISPR guide RNA therapeutic pipeline to make RNA phosphoramidites fastest-growing phosphoramidite category 282
17.2.1.1.3 Modified phosphoramidites 285
17.2.1.1.3.1 Modified phosphoramidites to continue to gain importance as oligonucleotide complexity increases 285
17.2.1.2 Activators/Coupling reagents 289
17.2.1.2.1 Migration from standard tetrazole to ETT- and BTT-based activators to raise coupling efficiency in GMP-scale RNA and modified-oligo synthesis 289
17.2.1.3 Deprotection reagents 292
17.2.1.3.1 Rising synthesis throughput and demand for milder, modification-compatible deprotection chemistries to sustain detritylation reagent consumption 292
17.2.1.4 Capping reagents 296
17.2.1.4.1 Tightening n-1 impurity specifications for therapeutic oligonucleotides to lift demand for validated, high-purity capping reagent lots 296
17.2.1.5 Other reagents 299
17.2.2 SOLID SUPPORTS 302
17.2.2.1 Shift toward high-loading co-polymer CPG and single-use synthesis cassettes to support long-chain, GMP-scale oligonucleotide production 302
17.2.3 OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES 306
17.2.3.1 Tightening GMP purity specifications for therapeutic oligonucleotides to drive demand for purification and QC consumables 306
17.3 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT 309
17.3.1 ADOPTION OF FLOW-THROUGH, GMP-COMPLIANT SYNTHESIS PLATFORMS TO SCALE OLIGONUCLEOTIDE MANUFACTURING FROM RESEARCH THROUGH COMMERCIAL PRODUCTION 309
18 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION 313
18.1 INTRODUCTION 314
18.2 RESEARCH APPLICATIONS 314
18.2.1 HIGH-VOLUME CONSUMPTION OF SYNTHESIS PRODUCTS ACROSS GENOMICS AND MOLECULAR BIOLOGY RESEARCH TO DRIVE GROWTH 314
18.3 THERAPEUTIC DEVELOPMENT 318
18.3.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO BOOST MARKET 318
18.4 DIAGNOSTIC APPLICATIONS 321
18.4.1 DIAGNOSTICS APPLICATIONS TO CONTINUE TO EXPAND WITH INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE 321
19 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER 325
19.1 INTRODUCTION 326
19.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 326
19.2.1 INCREASING INVESTMENTS IN OLIGONUCLEOTIDE DRUG DEVELOPMENT AND MANUFACTURING TO SUPPORT MARKET GROWTH 326
19.3 CROS & CDMOS 330
19.3.1 INCREASING OUTSOURCING OF OLIGONUCLEOTIDE MANUFACTURING TO DRIVE MARKET GROWTH 330
19.4 DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES 334
19.4.1 EXPANDED USE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS WITH GROWTH OF MOLECULAR DIAGNOSTICS TO BOOST DEMAND 334
19.5 ACADEMIC & RESEARCH INSTITUTES 337
19.5.1 ACADEMICS & RESEARCH INSTITUTES TO CONTINUE TO PROVIDE STABLE DEMAND DRIVEN BY EXPANDING GENOMICS AND LIFE SCIENCE RESEARCH 337
20 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION 341
20.1 INTRODUCTION 342
20.2 NORTH AMERICA 342
20.2.1 US 351
20.2.1.1 Mature ecosystem across oligo-based therapeutics, synthesized oligonucleotides, and oligonucleotide synthesis products to drive market growth 351
20.2.2 CANADA 359
20.2.2.1 Strong academic research ecosystem to support market growth 359
20.3 EUROPE 367
20.3.1 GERMANY 375
20.3.1.1 Established capabilities for development and manufacturing of
oligo-based therapeutics to drive market growth 375
20.3.2 UK 383
20.3.2.1 Established national programs to encourage utilization of oligonucleotide synthesis products 383
20.3.3 FRANCE 391
20.3.3.1 Increase in RNA-related research by biotechnology companies and academic institutions to drive market growth 391
20.3.4 ITALY 399
20.3.4.1 High demand for molecular diagnostics to favor adoption of oligonucleotide synthesis products 399
20.3.5 SPAIN 406
20.3.5.1 Government organizations investing in oligonucleotide-related research activities to drive market growth 406
20.3.6 REST OF EUROPE 413
20.4 ASIA PACIFIC 421
20.4.1 JAPAN 430
20.4.1.1 Expanding collaboration between pharma companies and academic institutions for development of oligonucleotide therapeutics to drive market growth 430
20.4.2 CHINA 438
20.4.2.1 Robust network of domestic companies offering oligonucleotide products to support market growth 438
20.4.3 INDIA 446
20.4.3.1 Expanding presence of domestic service providers to offer high-quality DNA and RNA oligonucleotides for research and diagnostics 446
20.4.4 SOUTH KOREA 453
20.4.4.1 High demand for custom oligonucleotide synthesis services to support market growth 453
20.4.5 AUSTRALIA 461
20.4.5.1 Well-established biomedical research sector to favor utilization of oligonucleotide synthesis products 461
20.4.6 REST OF ASIA PACIFIC 469
20.5 LATIN AMERICA 477
20.5.1 BRAZIL 485
20.5.1.1 Government initiatives aimed at strengthening genomic surveillance to offer market expansion opportunities 485
20.5.2 MEXICO 493
20.5.2.1 Growing network of pharmaceutical manufacturers and diagnostic laboratories to offer market expansion opportunities 493
20.5.3 ARGENTINA 501
20.5.3.1 Increasing investment by academic institutions in oligonucleotide-based research to offer market expansion opportunities 501
20.5.4 REST OF LATIN AMERICA 506
20.6 MIDDLE EAST 511
20.6.1 GCC COUNTRIES 519
20.6.1.1 Saudi Arabia 527
20.6.1.1.1 National genomics initiatives to encourage adoption of oligonucleotide synthesis products 527
20.6.1.2 UAE 535
20.6.1.2.1 Government-driven initiatives and substantial investments to improve UAE's capabilities in life science industry 535
20.6.1.3 Rest of GCC Countries 543
20.6.2 REST OF MIDDLE EAST 551
20.7 AFRICA 559
20.7.1 GROWING INVESTMENTS IN PUBLIC HEALTH DIAGNOSTICS AND GENOMIC SURVEILLANCE ACTIVITIES TO DRIVE MARKET GROWTH 559
21 COMPETITIVE LANDSCAPE 567
21.1 INTRODUCTION 567
21.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 567
21.2.1 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2023–2026 567
21.2.2 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2023–2026 569
21.3 REVENUE ANALYSIS, 2021–2025 572
21.3.1 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET,
2021–2025 572
21.3.2 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2021–2025 572
21.4 MARKET SHARE ANALYSIS, 2025 573
21.4.1 MARKET SHARE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2025 573
21.4.2 MARKET SHARE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2025 575
21.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE-BASED DRUGS MARKET), 2025 578
21.5.1 STARS 578
21.5.2 EMERGING LEADERS 578
21.5.3 PERVASIVE PLAYERS 578
21.5.4 PARTICIPANTS 578
21.5.5 COMPANY FOOTPRINT: OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2025 580
21.5.5.1 Company footprint 580
21.5.5.2 Region footprint 580
21.5.5.3 Drug type footprint 581
21.5.5.4 Therapeutic area footprint 582
21.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET), 2025 582
21.6.1 STARS 583
21.6.2 EMERGING LEADERS 583
21.6.3 PERVASIVE PLAYERS 583
21.6.4 PARTICIPANTS 583
21.6.5 COMPANY FOOTPRINT: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2025 585
21.6.5.1 Company footprint 585
21.6.5.2 Region footprint 586
21.6.5.3 Product type footprint 587
21.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 588
21.7.1 PROGRESSIVE COMPANIES 588
21.7.2 RESPONSIVE COMPANIES 588
21.7.3 DYNAMIC COMPANIES 588
21.7.4 STARTING BLOCKS 588
21.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 590
21.7.5.1 Detailed list of key startups/SMEs 590
21.7.5.2 Competitive benchmarking of key startups/SMEs 591
21.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 592
21.9 COMPANY VALUATION & FINANCIAL METRICS 594
21.9.1 COMPANY VALUATION & FINANCIAL METRICS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES PLAYERS 594
21.9.2 COMPANY VALUATION & FINANCIAL METRICS FOR OLIGONUCLEOTIDE-BASE DRUGS PLAYERS 595
21.10 COMPETITIVE SCENARIO 596
21.10.1 PRODUCT APPROVALS 596
21.10.2 DEALS 597
21.10.3 EXPANSIONS 598
22 COMPANY PROFILES 600
22.1 OLIGONUCLEOTIDE-BASED DRUG COMPANIES 600
22.1.1 ALNYLAM PHARMACEUTICALS, INC. 600
22.1.1.1 Business overview 600
22.1.1.2 Products offered 601
22.1.1.3 Recent developments 602
22.1.1.3.1 Product approvals 602
22.1.1.3.2 Deals 602
22.1.1.3.3 Expansions 603
22.1.1.4 MnM view 603
22.1.1.4.1 Key strengths 603
22.1.1.4.2 Strategic choices 603
22.1.1.4.3 Weaknesses & competitive threats 603
22.1.2 BIOGEN INC. 604
22.1.2.1 Business overview 604
22.1.2.2 Products offered 605
22.1.2.3 Recent developments 606
22.1.2.3.1 Product approvals 606
22.1.2.3.2 Deals 606
22.1.2.3.3 Expansions 607
22.1.2.4 MnM view 607
22.1.2.4.1 Key strengths 607
22.1.2.4.2 Strategic choices 607
22.1.2.4.3 Weaknesses & competitive threats 607
22.1.3 NOVARTIS AG 608
22.1.3.1 Business overview 608
22.1.3.2 Products offered 609
22.1.3.3 Recent developments 610
22.1.3.3.1 Product approvals 610
22.1.3.3.2 Deals 610
22.1.3.4 MnM view 611
22.1.3.4.1 Key strengths 611
22.1.3.4.2 Strategic choices 611
22.1.3.4.3 Weaknesses & competitive threats 611
22.1.4 SAREPTA THERAPEUTICS, INC. 612
22.1.4.1 Business overview 612
22.1.4.2 Products offered 613
22.1.4.3 Recent developments 614
22.1.4.3.1 Product approvals 614
22.1.4.3.2 Deals 614
22.1.4.3.3 Expansions 614
22.1.4.4 MnM view 615
22.1.4.4.1 Key strengths 615
22.1.4.4.2 Strategic choices 615
22.1.4.4.3 Weaknesses & competitive threats 615
22.1.5 ASTELLAS PHARMA INC. 616
22.1.5.1 Business overview 616
22.1.5.2 Products offered 617
22.1.5.3 Recent developments 618
22.1.5.3.1 Product approvals 618
22.1.5.3.2 Deals 618
22.1.5.4 MnM view 619
22.1.5.4.1 Key strengths 619
22.1.5.4.2 Strategic choices 619
22.1.5.4.3 Weaknesses & competitive threats 619
22.1.6 ASTRAZENECA 620
22.1.6.1 Business overview 620
22.1.6.2 Products offered 621
22.1.6.3 Recent developments 622
22.1.6.3.1 Product approvals 622
22.1.6.3.2 Deals 622
22.1.7 JAZZ PHARMACEUTICALS PLC 623
22.1.7.1 Business overview 623
22.1.7.2 Products offered 624
22.1.8 GERON CORPORATION 625
22.1.8.1 Business overview 625
22.1.8.2 Products offered 626
22.1.8.3 Recent developments 626
22.1.8.3.1 Product approvals 626
22.1.8.3.2 Deals 626
22.1.9 IONIS PHARMACEUTICALS, INC. 627
22.1.9.1 Business overview 627
22.1.9.2 Products offered 628
22.1.9.3 Recent developments 629
22.1.9.3.1 Product approvals 629
22.1.9.3.2 Deals 630
22.1.9.3.3 Expansions 630
22.1.10 NIPPON SHINYAKU, CO. LTD. (NS PHARMA, INC.) 631
22.1.10.1 Business overview 631
22.1.10.2 Products offered 632
22.1.10.3 Recent developments 633
22.1.10.3.1 Deals 633
22.1.11 NOVO NORDISK A/S 634
22.1.11.1 Business overview 634
22.1.11.2 Products offered 635
22.1.11.3 Recent developments 636
22.1.11.3.1 Product approvals 636
22.1.12 ARROWHEAD PHARMACEUTICALS, INC. 637
22.1.12.1 Business overview 637
22.1.12.2 Products offered 638
22.1.12.3 Recent developments 638
22.1.12.3.1 Product launches & approvals 638
22.1.12.3.2 Deals 639
22.1.13 SANOFI 640
22.1.13.1 Business overview 640
22.1.13.2 Products offered 641
22.1.13.3 Recent developments 642
22.1.13.3.1 Product approvals 642
22.2 OLIGONUCLEOTIDE SYNTHESIS & SYNTHESIZED OLIGONUCLEOTIDE COMPANIES 643
22.2.1 THERMO FISHER SCIENTIFIC INC. 643
22.2.1.1 Business overview 643
22.2.1.2 Products offered 644
22.2.1.3 Recent developments 647
22.2.1.3.1 Expansions 647
22.2.1.4 MnM view 647
22.2.1.4.1 Key strengths 647
22.2.1.4.2 Strategic choices 647
22.2.1.4.3 Weaknesses & competitive threats 647
22.2.2 MERCK KGAA 648
22.2.2.1 Business overview 648
22.2.2.2 Products offered 649
22.2.2.3 Recent developments 652
22.2.2.3.1 Expansions 652
22.2.2.4 MnM view 653
22.2.2.4.1 Key strengths 653
22.2.2.4.2 Strategic choices 653
22.2.2.4.3 Weaknesses & competitive threats 653
22.2.3 DANAHER CORPORATION 654
22.2.3.1 Business overview 654
22.2.3.2 Products offered 655
22.2.3.3 Recent developments 659
22.2.3.3.1 Service launches 659
22.2.3.3.2 Deals 659
22.2.3.3.3 Expansions 659
22.2.3.4 MnM view 660
22.2.3.4.1 Key strengths 660
22.2.3.4.2 Strategic choices 660
22.2.3.4.3 Weaknesses & competitive threats 660
22.2.4 EUROFINS SCIENTIFIC 661
22.2.4.1 Business overview 661
22.2.4.2 Products offered 662
22.2.4.3 Recent developments 663
22.2.4.3.1 Deals 663
22.2.4.3.2 Expansions 664
22.2.4.4 MnM view 664
22.2.4.4.1 Key strengths 664
22.2.4.4.2 Strategic choices 664
22.2.4.4.3 Weaknesses & competitive threats 664
22.2.5 AGILENT TECHNOLOGIES, INC. 665
22.2.5.1 Business overview 665
22.2.5.2 Products offered 666
22.2.5.3 Recent developments 668
22.2.5.3.1 Deals 668
22.2.5.3.2 Expansions 668
22.2.6 LGC LIMITED 669
22.2.6.1 Business overview 669
22.2.6.2 Products offered 670
22.2.6.3 Recent developments 672
22.2.6.3.1 Deals 672
22.2.6.4 MnM view 672
22.2.6.4.1 Key strengths 672
22.2.6.4.2 Strategic choices 672
22.2.6.4.3 Weaknesses & competitive threats 673
22.2.7 TWIST BIOSCIENCE 674
22.2.7.1 Business overview 674
22.2.7.2 Products offered 675
22.2.7.3 Recent developments 676
22.2.7.3.1 Product/Service launches 676
22.2.7.3.2 Deals 676
22.2.8 GENSCRIPT 677
22.2.8.1 Business overview 677
22.2.8.2 Products offered 678
22.2.8.3 Recent developments 680
22.2.8.3.1 Product/Service launches 680
22.2.8.3.2 Deals 680
22.2.8.3.3 Expansions 680
22.2.9 MARAVAI LIFESCIENCES 681
22.2.9.1 Business overview 681
22.2.9.2 Products offered 682
22.2.9.3 Recent developments 685
22.2.9.3.1 Product/Service launches 685
22.2.9.3.2 Deals 686
22.2.9.3.3 Expansions 686
22.2.9.4 MnM view 687
22.2.9.4.1 Key strengths 687
22.2.9.4.2 Strategic choices 687
22.2.9.4.3 Weaknesses & competitive threats 687
22.2.10 KANEKA CORPORATION 688
22.2.10.1 Business overview 688
22.2.10.2 Products offered 689
22.2.10.3 Recent developments 691
22.2.10.3.1 Expansions 691
22.2.11 AZENTA US INC. 692
22.2.11.1 Business overview 692
22.2.11.2 Products offered 693
22.2.11.3 Recent developments 694
22.2.11.3.1 Product/Service launches 694
22.2.11.3.2 Deals 694
22.2.12 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S) 695
22.2.12.1 Business overview 695
22.2.12.2 Products offered 695
22.2.13 BIOLEGIO B.V. 696
22.2.13.1 Business overview 696
22.2.13.2 Products offered 697
22.2.14 BIOLYTIC LAB PERFORMANCE, INC. 698
22.2.14.1 Business overview 698
22.2.14.2 Products offered 698
22.2.14.3 Recent developments 699
22.2.14.3.1 Product/Service launches 699
22.2.15 REVVITY (THROUGH SUBSIDIARY HORIZON DISCOVERY LTD.) 700
22.2.15.1 Business overview 700
22.2.15.2 Products offered 702
22.2.15.3 Recent developments 703
22.2.15.3.1 Product/Service launches 703
22.2.16 BIO-SYNTHESIS, INC. 704
22.2.16.1 Business overview 704
22.2.16.2 Products offered 704
22.2.17 CREATIVE BIOGENE 707
22.2.17.1 Business overview 707
22.2.17.2 Products offered 707
22.2.18 REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE) 710
22.2.18.1 Business overview 710
22.2.18.2 Products offered 711
22.2.19 BIOCOMMA LIMITED 712
22.2.19.1 Business overview 712
22.2.19.2 Products offered 712
23 RESEARCH METHODOLOGY 716
23.1 RESEARCH DATA 716
23.1.1 SECONDARY DATA 717
23.1.1.1 Key secondary sources 717
23.1.1.2 Key data from secondary research 717
23.1.2 PRIMARY DATA 718
23.1.2.1 Key primary participants 718
23.1.2.2 Breakdown of primary interviews 719
23.1.2.3 Key data from primary sources 719
23.2 MARKET SIZE ESTIMATION 720
23.2.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET ESTIMATION, 2025 720
23.2.1.1 Approach 1: Company revenue analysis-based estimation
(bottom-up) 720
23.2.1.2 Approach 2: Secondary research 722
23.2.1.3 Approach 3: Primary research 722
23.2.1.4 Key industry insights 723
23.2.1.5 Approach 3: MnM repository analysis 723
23.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025 724
23.3 MARKET GROWTH RATE PROJECTIONS 726
23.4 DATA TRIANGULATION 729
23.5 RESEARCH ASSUMPTIONS 730
23.6 RESEARCH LIMITATIONS & RISK ASSESSMENT 731
24 APPENDIX 732
24.1 DISCUSSION GUIDE 732
24.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 739
24.3 CUSTOMIZATION OPTIONS 741
24.4 RELATED REPORTS 741
24.5 AUTHOR DETAILS 742
圖表清單 List of Tables & Figures
TABLE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET: INCLUSIONS & EXCLUSIONS 66
TABLE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS 83
TABLE 3 OLIGONUCLEOTIDE-BASED DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS 94
TABLE 4 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: PORTER’S FIVE FORCES ANALYSIS 96
TABLE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET: ROLE IN ECOSYSTEM 101
TABLE 6 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGOS, BY KEY PLAYER, 2023–2025 102
TABLE 7 AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS,
BY KEY PLAYER, 2023–2025 103
TABLE 8 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIZERS,
BY REGION, 2025 104
TABLE 9 OLIGONUCLEOTIDE SYNTHESIS MARKET: KEY CONFERENCES & EVENTS,
2026–2027 105
TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES 108
TABLE 11 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE SYNTHESIS MARKETCASE STUDIES OF AI IMPLEMENTATION IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET 119
TABLE 12 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN OLIGONUCLEOTIDE
SYNTHESIS MARKET 120
TABLE 13 OLIGONUCLEOTIDE SYNTHESIS MARKET: INDICATIVE LIST OF PATENTS, 2025 121
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 123
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 124
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 124
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 125
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 125
TABLE 19 REIMBURSEMENT SCENARIO FOR MAJOR COMMERCIAL OLIGONUCLEOTIDE THERAPEUTICS 128
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 133
TABLE 21 KEY BUYING CRITERIA, BY END USER 133
TABLE 22 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 137
TABLE 23 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,
2024–2031 (USD MILLION) 138
TABLE 24 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 25 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 139
TABLE 26 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 139
TABLE 27 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 140
TABLE 28 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,
2024–2031 (USD MILLION) 140
TABLE 29 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 30 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY PRODUCT,
2024–2031 (VIALS/PREFILLED SYRINGES) 141
TABLE 31 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION,
2024–2031 (USD MILLION) 142
TABLE 32 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 33 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 143
TABLE 34 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 144
TABLE 35 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 36 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION,
2024–2031 (USD MILLION) 145
TABLE 37 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 38 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY REGION,
2024–2031 (USD MILLION) 146
TABLE 39 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 40 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 41 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 42 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 43 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 148
TABLE 44 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 45 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION) 150
TABLE 46 APPROVED ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS 151
TABLE 47 ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY REGION,
2024–2031 (USD MILLION) 152
TABLE 48 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 49 EUROPE: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 50 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 51 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 52 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET,
BY REGION, 2024–2031 (USD MILLION) 154
TABLE 53 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 54 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS 155
TABLE 55 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,
2024–2031 (USD MILLION) 156
TABLE 56 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 57 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 58 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 59 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 60 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION) 158
TABLE 61 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 62 OTHER APPROVED OLIGONUCLEOTIDE-BASED DRUGS 159
TABLE 63 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,
2024–2031 (USD MILLION) 160
TABLE 64 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 65 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 161
TABLE 66 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 67 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 68 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION) 162
TABLE 69 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 70 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 165
TABLE 71 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY REGION, 2024–2031 (USD MILLION) 166
TABLE 72 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 73 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 74 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 75 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 76 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY REGION, 2024–2031 (USD MILLION) 168
TABLE 77 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 78 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS,
BY REGION, 2024–2031 (USD MILLION) 170
TABLE 79 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 80 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 81 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 82 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 83 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 172
TABLE 84 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 85 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES,
BY REGION, 2024–2031 (USD MILLION) 174
TABLE 86 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 87 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 88 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 89 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 90 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION) 176
TABLE 91 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 92 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2024–2031 (USD MILLION) 178
TABLE 93 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 94 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 95 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 96 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 181
TABLE 97 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION) 182
TABLE 98 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 99 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS,
BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 100 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 101 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 102 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION) 184
TABLE 103 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 104 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY REGION,
2024–2031 (USD MILLION) 186
TABLE 105 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS,
BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 106 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS,
BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 107 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS,
BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 108 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS,
BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 109 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS,
BY REGION, 2024–2031 (USD MILLION) 188
TABLE 110 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS,
BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 111 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS,
BY REGION, 2024–2031 (USD MILLION) 190
TABLE 112 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 113 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 114 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 115 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 116 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY REGION, 2024–2031 (USD MILLION) 192
TABLE 117 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 118 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 194
TABLE 119 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER
END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 120 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 121 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 122 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER
END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 123 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER
END USERS, BY REGION, 2024–2031 (USD MILLION) 196
TABLE 124 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER
END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 125 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 199
TABLE 126 PRIMERS MARKET, BY REGION, 2024–2031 (USD MILLION) 200
TABLE 127 NORTH AMERICA: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 128 EUROPE: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 129 ASIA PACIFIC: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 130 LATIN AMERICA: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 131 MIDDLE EAST: PRIMERS MARKET, BY REGION, 2024–2031 (USD MILLION) 202
TABLE 132 GCC COUNTRIES: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 133 PROBES MARKET, BY REGION, 2024–2031 (USD MILLION) 203
TABLE 134 NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 135 EUROPE: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 136 ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 137 LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 138 MIDDLE EAST: PROBES MARKET, BY REGION, 2024–2031 (USD MILLION) 205
TABLE 139 GCC COUNTRIES: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 140 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 207
TABLE 141 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 207
TABLE 142 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 208
TABLE 143 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 208
TABLE 144 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 209
TABLE 145 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY REGION,
2024–2031 (USD MILLION) 209
TABLE 146 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 209
TABLE 147 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 210
TABLE 148 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 211
TABLE 149 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 211
TABLE 150 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 212
TABLE 151 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 212
TABLE 152 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY REGION,
2024–2031 (USD MILLION) 213
TABLE 153 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 213
TABLE 154 OTHER OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 214
TABLE 155 NORTH AMERICA: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 214
TABLE 156 EUROPE: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 215
TABLE 157 ASIA PACIFIC: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 215
TABLE 158 LATIN AMERICA: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 216
TABLE 159 MIDDLE EAST: OTHER OLIGONUCLEOTIDES MARKET, BY REGION,
2024–2031 (USD MILLION) 216
TABLE 160 GCC COUNTRIES: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 216
TABLE 161 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION) 218
TABLE 162 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 219
TABLE 163 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 219
TABLE 164 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 220
TABLE 165 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 220
TABLE 166 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 221
TABLE 167 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION,
2024–2031 (USD MILLION) 221
TABLE 168 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 221
TABLE 169 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION,
2024–2031 (USD MILLION) 222
TABLE 170 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 171 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 223
TABLE 172 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 224
TABLE 173 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 174 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION,
2024–2031 (USD MILLION) 225
TABLE 175 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 176 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 227
TABLE 177 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 228
TABLE 178 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 179 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 180 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 181 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 182 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 230
TABLE 183 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 184 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2024–2031 (USD MILLION) 231
TABLE 185 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 232
TABLE 186 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 187 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 188 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 189 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 190 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 234
TABLE 191 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 192 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 235
TABLE 193 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 194 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS,
BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 195 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 196 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 197 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 237
TABLE 198 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 199 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 238
TABLE 200 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 201 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 202 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 203 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 204 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 240
TABLE 205 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 206 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAEPUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 241
TABLE 207 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAEPUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 208 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 209 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 210 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 211 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 244
TABLE 212 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 213 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 245
TABLE 214 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 215 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 216 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 217 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 218 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 247
TABLE 219 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 220 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 249
TABLE 221 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 250
TABLE 222 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 250
TABLE 223 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 224 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 225 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 252
TABLE 226 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 252
TABLE 227 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 252
TABLE 228 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION) 253
TABLE 229 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 254
TABLE 230 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS,
BY COUNTRY, 2024–2031 (USD MILLION) 254
TABLE 231 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 232 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 233 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION) 256
TABLE 234 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 235 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 257
TABLE 236 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY,
2024–2031 (USD MILLION) 257
TABLE 237 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY,
2024–2031 (USD MILLION) 258
TABLE 238 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY,
2024–2031 (USD MILLION) 258
TABLE 239 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY,
2024–2031 (USD MILLION) 259
TABLE 240 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 259
TABLE 241 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY,
2024–2031 (USD MILLION) 259
TABLE 242 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 260
TABLE 243 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 244 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 245 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 246 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 247 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 263
TABLE 248 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 249 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 265
TABLE 250 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY REGION, 2024–2031 (USD MILLION) 266
TABLE 251 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 252 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 253 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 254 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 255 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 269
TABLE 256 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 257 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 269
TABLE 258 OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 270
TABLE 259 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 261 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 272
TABLE 262 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 272
TABLE 263 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 273
TABLE 264 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 273
TABLE 265 OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 274
TABLE 266 PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY REGION,
2024–2031 (USD MILLION) 275
TABLE 267 NORTH AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 268 EUROPE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 276
TABLE 269 ASIA PACIFIC: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 276
TABLE 270 LATIN AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 271 MIDDLE EAST: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION) 277
TABLE 272 GCC COUNTRIES: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 273 PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 278
TABLE 274 DNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION) 279
TABLE 275 NORTH AMERICA: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 279
TABLE 276 EUROPE: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 280
TABLE 277 ASIA PACIFIC: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 280
TABLE 278 LATIN AMERICA: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 281
TABLE 279 MIDDLE EAST: DNA PHOSPHORAMIDITES MARKET, BY REGION,
2024–2031 (USD MILLION) 281
TABLE 280 GCC COUNTRIES: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 281
TABLE 281 RNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION) 282
TABLE 282 NORTH AMERICA: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 283
TABLE 283 EUROPE: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 283
TABLE 284 ASIA PACIFIC: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 284
TABLE 285 LATIN AMERICA: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 284
TABLE 286 MIDDLE EAST: RNA PHOSPHORAMIDITES MARKET, BY REGION,
2024–2031 (USD MILLION) 285
TABLE 287 GCC COUNTRIES: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 285
TABLE 288 MODIFIED PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION) 286
TABLE 289 NORTH AMERICA: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 286
TABLE 290 EUROPE: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 287
TABLE 291 ASIA PACIFIC: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 287
TABLE 292 LATIN AMERICA: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 288
TABLE 293 MIDDLE EAST: MODIFIED PHOSPHORAMIDITES MARKET, BY REGION,
2024–2031 (USD MILLION) 288
TABLE 294 GCC COUNTRIES: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 288
TABLE 295 ACTIVATORS/COUPLING REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 289
TABLE 296 NORTH AMERICA: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 290
TABLE 297 EUROPE: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 290
TABLE 298 ASIA PACIFIC: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 291
TABLE 299 LATIN AMERICA: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 291
TABLE 300 MIDDLE EAST: ACTIVATORS/COUPLING REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 292
TABLE 301 GCC COUNTRIES: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 302 DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 293
TABLE 303 NORTH AMERICA: DEPROTECTION REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 293
TABLE 304 EUROPE: DEPROTECTION REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 294
TABLE 305 ASIA PACIFIC: DEPROTECTION REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 294
TABLE 306 LATIN AMERICA: DEPROTECTION REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 295
TABLE 307 MIDDLE EAST: DEPROTECTION REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 295
TABLE 308 GCC COUNTRIES: DEPROTECTION REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 295
TABLE 309 CAPPING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 296
TABLE 310 NORTH AMERICA: CAPPING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 297
TABLE 311 EUROPE: CAPPING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 297
TABLE 312 ASIA PACIFIC: CAPPING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 298
TABLE 313 LATIN AMERICA: CAPPING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 298
TABLE 314 MIDDLE EAST: CAPPING REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 298
TABLE 315 GCC COUNTRIES: CAPPING REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 299
TABLE 316 OTHER REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 299
TABLE 317 NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 300
TABLE 318 EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 300
TABLE 319 ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 301
TABLE 320 LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 301
TABLE 321 MIDDLE EAST: OTHER REAGENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 301
TABLE 322 GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 302
TABLE 323 SOLID SUPPORTS MARKET, BY REGION, 2024–2031 (USD MILLION) 303
TABLE 324 NORTH AMERICA: SOLID SUPPORTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 303
TABLE 325 EUROPE: SOLID SUPPORTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 304
TABLE 326 ASIA PACIFIC: SOLID SUPPORTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 304
TABLE 327 LATIN AMERICA: SOLID SUPPORTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 305
TABLE 328 MIDDLE EAST: SOLID SUPPORTS MARKET, BY REGION, 2024–2031 (USD MILLION) 305
TABLE 329 GCC COUNTRIES: SOLID SUPPORTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 305
TABLE 330 OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 306
TABLE 331 NORTH AMERICA: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 307
TABLE 332 EUROPE: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 307
TABLE 333 ASIA PACIFIC: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 308
TABLE 334 LATIN AMERICA: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 308
TABLE 335 MIDDLE EAST: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET,
BY REGION, 2024–2031 (USD MILLION) 309
TABLE 336 GCC COUNTRIES: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 309
TABLE 337 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION,
2024–2031 (USD MILLION) 310
TABLE 338 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 310
TABLE 339 EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 340 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 341 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 312
TABLE 342 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 312
TABLE 343 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 312
TABLE 344 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 314
TABLE 345 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 315
TABLE 346 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 315
TABLE 347 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 316
TABLE 348 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 316
TABLE 349 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 317
TABLE 350 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 317
TABLE 351 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 317
TABLE 352 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 318
TABLE 353 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 319
TABLE 354 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 319
TABLE 355 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 320
TABLE 356 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 320
TABLE 357 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 321
TABLE 358 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 321
TABLE 359 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 322
TABLE 360 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 322
TABLE 361 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 323
TABLE 362 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 323
TABLE 363 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 324
TABLE 364 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 324
TABLE 365 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 324
TABLE 366 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 326
TABLE 367 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 327
TABLE 368 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 327
TABLE 369 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 328
TABLE 370 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 328
TABLE 371 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 329
TABLE 372 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,
2024–2031 (USD MILLION) 329
TABLE 373 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 330
TABLE 374 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS,
BY REGION, 2024–2031 (USD MILLION) 331
TABLE 375 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 331
TABLE 376 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 332
TABLE 377 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 332
TABLE 378 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 333
TABLE 379 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION) 333
TABLE 380 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 333
TABLE 381 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 334
TABLE 382 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY,
2024–2031 (USD MILLION) 335
TABLE 383 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY,
2024–2031 (USD MILLION) 335
TABLE 384 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY,
2024–2031 (USD MILLION) 336
TABLE 385 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY,
2024–2031 (USD MILLION) 336
TABLE 386 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION,
2024–2031 (USD MILLION) 337
TABLE 387 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY,
2024–2031 (USD MILLION) 337
TABLE 388 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 338
TABLE 389 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 338
TABLE 390 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 339
TABLE 391 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 339
TABLE 392 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 340
TABLE 393 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 340
TABLE 394 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 340
TABLE 395 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION) 342
TABLE 396 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 343
TABLE 397 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 344
TABLE 398 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 344
TABLE 399 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 345
TABLE 400 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION) 345
TABLE 401 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 346
TABLE 402 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION) 346
TABLE 403 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 347
TABLE 404 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 347
TABLE 405 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION) 348
TABLE 406 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 348
TABLE 407 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 408 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 409 NORTH AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 350
TABLE 410 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 350
TABLE 411 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 351
TABLE 412 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 352
TABLE 413 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 352
TABLE 414 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 353
TABLE 415 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 353
TABLE 416 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 354
TABLE 417 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 354
TABLE 418 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 355
TABLE 419 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 420 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 356
TABLE 421 US: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 356
TABLE 422 US: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 357
TABLE 423 US: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 357
TABLE 424 US: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 358
TABLE 425 US: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 358
TABLE 426 US: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 359
TABLE 427 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 360
TABLE 428 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 360
TABLE 429 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 361
TABLE 430 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 361
TABLE 431 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 362
TABLE 432 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 362
TABLE 433 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 363
TABLE 434 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 363
TABLE 435 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 364
TABLE 436 CANADA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 364
TABLE 437 CANADA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 365
TABLE 438 CANADA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 365
TABLE 439 CANADA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 366
TABLE 440 CANADA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 366
TABLE 441 CANADA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 367
TABLE 442 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 368
TABLE 443 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 368
TABLE 444 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 369
TABLE 445 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 369
TABLE 446 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 370
TABLE 447 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 370
TABLE 448 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 371
TABLE 449 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 371
TABLE 450 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 372
TABLE 451 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 372
TABLE 452 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 372
TABLE 453 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 373
TABLE 454 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 373
TABLE 455 EUROPE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 374
TABLE 456 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 374
TABLE 457 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 375
TABLE 458 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 376
TABLE 459 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 376
TABLE 460 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 377
TABLE 461 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 377
TABLE 462 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 378
TABLE 463 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 378
TABLE 464 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 379
TABLE 465 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 379
TABLE 466 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 380
TABLE 467 GERMANY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 380
TABLE 468 GERMANY: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 381
TABLE 469 GERMANY: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 381
TABLE 470 GERMANY: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 382
TABLE 471 GERMANY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 382
TABLE 472 GERMANY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 383
TABLE 473 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 384
TABLE 474 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 384
TABLE 475 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 385
TABLE 476 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 385
TABLE 477 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 386
TABLE 478 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 386
TABLE 479 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 387
TABLE 480 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 481 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 388
TABLE 482 UK: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 388
TABLE 483 UK: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 484 UK: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 389
TABLE 485 UK: PHOSPHORAMIDITE BUILDING BLOCKSMARKET, BY TYPE,
2024–2031 (USD MILLION) 390
TABLE 486 UK: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 390
TABLE 487 UK: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 391
TABLE 488 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 392
TABLE 489 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 392
TABLE 490 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 393
TABLE 491 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 393
TABLE 492 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 394
TABLE 493 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 394
TABLE 494 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 395
TABLE 495 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 395
TABLE 496 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 396
TABLE 497 FRANCE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 396
TABLE 498 FRANCE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 397
TABLE 499 FRANCE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 397
TABLE 500 FRANCE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 398
TABLE 501 FRANCE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 398
TABLE 502 FRANCE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 399
TABLE 503 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 400
TABLE 504 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 400
TABLE 505 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 401
TABLE 506 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 401
TABLE 507 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 402
TABLE 508 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 402
TABLE 509 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 402
TABLE 510 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 403
TABLE 511 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 403
TABLE 512 ITALY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 403
TABLE 513 ITALY: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 514 ITALY: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 404
TABLE 515 ITALY: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY PHTYPE,
2024–2031 (USD MILLION) 405
TABLE 516 ITALY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 405
TABLE 517 ITALY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 406
TABLE 518 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 407
TABLE 519 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 407
TABLE 520 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 408
TABLE 521 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 408
TABLE 522 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 409
TABLE 523 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 409
TABLE 524 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 409
TABLE 525 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 526 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 410
TABLE 527 SPAIN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 410
TABLE 528 SPAIN: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 411
TABLE 529 SPAIN: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 411
TABLE 530 SPAIN: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 412
TABLE 531 SPAIN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 412
TABLE 532 SPAIN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 413
TABLE 533 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 414
TABLE 534 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 414
TABLE 535 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 415
TABLE 536 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION) 415
TABLE 537 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 416
TABLE 538 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION) 416
TABLE 539 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 417
TABLE 540 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 417
TABLE 541 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION) 418
TABLE 542 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 418
TABLE 543 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 544 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 545 REST OF EUROPE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 420
TABLE 546 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 420
TABLE 547 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 421
TABLE 548 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 423
TABLE 549 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 423
TABLE 550 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 424
TABLE 551 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 424
TABLE 552 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 425
TABLE 553 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 425
TABLE 554 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 426
TABLE 555 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 426
TABLE 556 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 427
TABLE 557 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 427
TABLE 558 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 428
TABLE 559 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 428
TABLE 560 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 429
TABLE 561 ASIA PACIFIC: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 429
TABLE 562 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 430
TABLE 563 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 430
TABLE 564 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 431
TABLE 565 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 431
TABLE 566 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 432
TABLE 567 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 432
TABLE 568 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 432
TABLE 569 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 433
TABLE 570 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 433
TABLE 571 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 434
TABLE 572 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 434
TABLE 573 JAPAN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 435
TABLE 574 JAPAN: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 435
TABLE 575 JAPAN: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 436
TABLE 576 JAPAN: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 436
TABLE 577 JAPAN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 437
TABLE 578 JAPAN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 437
TABLE 579 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 438
TABLE 580 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 439
TABLE 581 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 439
TABLE 582 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 440
TABLE 583 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 440
TABLE 584 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 441
TABLE 585 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 441
TABLE 586 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 442
TABLE 587 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 442
TABLE 588 CHINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 443
TABLE 589 CHINA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 443
TABLE 590 CHINA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 444
TABLE 591 CHINA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY PHOTYPE,
2024–2031 (USD MILLION) 444
TABLE 592 CHINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 445
TABLE 593 CHINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 445
TABLE 594 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 446
TABLE 595 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 447
TABLE 596 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 447
TABLE 597 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 448
TABLE 598 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 448
TABLE 599 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE,
2024–2031 (USD MILLION) 449
TABLE 600 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 449
TABLE 601 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 450
TABLE 602 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER,
2024–2031 (USD MILLION) 450
TABLE 603 INDIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 451
TABLE 604 INDIA: OLIGONUCLEOTIDE REAGENTS & CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 451
TABLE 605 INDIA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 452
TABLE 606 INDIA: PHOSPHORAMIDITE BUILDING BLOCKSMARKET, BY TYPE,
2024–2031 (USD MILLION) 452
TABLE 607 INDIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 453
TABLE 608 INDIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 453
TABLE 609 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING,
2024–2031 (USD MILLION) 454
TABLE 610 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2024–2031 (USD MILLION) 454
TABLE 611 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 455
TABLE 612 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER,
2024–2031 (USD MILLION) 455
TABLE 613 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2024–2031 (USD MILLION) 456
TABLE 614 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION) 456
TABLE 615 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 457
TABLE 616 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 457
FIGURE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION &
REGIONS CONSIDERED 65
FIGURE 2 REGIONS CONSIDERED 66
FIGURE 3 OLIGONUCLEOTIDE SYNTHESIS MARKET: YEARS CONSIDERED 68
FIGURE 4 MARKET SCENARIO 71
FIGURE 5 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, 2024–2031 71
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2023–2026 72
FIGURE 7 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2023–2026 73
FIGURE 8 DISRUPTIONS INFLUENCING GROWTH OF OLIGONUCLEOTIDE SYNTHESIS MARKET 74
FIGURE 9 HIGH-GROWTH SEGMENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET,
2026–2031 75
FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN OLIGONUCLEOTIDE SYNTHESIS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 76
FIGURE 11 RISING COMMERCIALIZATION AND REGULATORY APPROVALS OF OLIGONUCLEOTIDE THERAPEUTICS TO PROPEL MARKET GROWTH 78
FIGURE 12 US AND OLIGONUCLEOTIDE-BASED DRUGS SEGMENT COMMANDED LARGEST MARKET SHARES IN 2025 79
FIGURE 13 MEXICO TO REGISTER HIGHER CAGR DURING FORECAST PERIOD 80
FIGURE 14 OLIGONUCLEOTIDE-BASED DRUGS TO DOMINATE MARKET DURING
FORECAST PERIOD 81
FIGURE 15 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 82
FIGURE 16 OLIGONUCLEOTIDE-BASED DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS 93
FIGURE 17 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: PORTER’S FIVE FORCES ANALYSIS 95
FIGURE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET: VALUE CHAIN ANALYSIS 99
FIGURE 19 OLIGONUCLEOTIDE SYNTHESIS MARKET: ECOSYSTEM ANALYSIS 100
FIGURE 20 OLIGONUCLEOTIDE-BASED DRUGS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 106
FIGURE 21 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 106
FIGURE 22 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 107
FIGURE 23 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET 118
FIGURE 24 TOP APPLICANTS/OWNER (COMPANIES) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS, 2015–2025 121
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 132
FIGURE 26 KEY BUYING CRITERIA, BY END USER 133
FIGURE 27 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 343
FIGURE 28 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 422
FIGURE 29 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2021–2025 572
FIGURE 30 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2021–2025 573
FIGURE 31 OLIGONUCLEOTIDE-BASED DRUGS MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2025 574
FIGURE 32 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2025 576
FIGURE 33 OLIGONUCLEOTIDE-BASED DRUGS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 579
FIGURE 34 OLIGONUCLEOTIDE-BASED DRUGS MARKET: COMPANY FOOTPRINT 580
FIGURE 35 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 584
FIGURE 36 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: COMPANY FOOTPRINT 585
FIGURE 37 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 589
FIGURE 38 OLIGONUCLEOTIDE-BASED DRUGS MARKET: BRAND/PRODUCT
COMPARATIVE ANALYSIS 592
FIGURE 39 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 593
FIGURE 40 EV/EBITDA OF KEY VENDORS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET 594
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET 594
FIGURE 42 EV/EBITDA OF KEY VENDORS IN OLIGONUCLEOTIDE-BASED DRUGS MARKET 595
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS IN OLIGONUCLEOTIDE-BASED DRUGS MARKET 595
FIGURE 44 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025) 601
FIGURE 45 BIOGEN INC.: COMPANY SNAPSHOT (2025) 605
FIGURE 46 NOVARTIS AG: COMPANY SNAPSHOT (2025) 609
FIGURE 47 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2025) 613
FIGURE 48 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2025) 617
FIGURE 49 ASTRAZENECA: COMPANY SNAPSHOT (2025) 621
FIGURE 50 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2025) 624
FIGURE 51 GERON CORPORATION: COMPANY SNAPSHOT (2025) 625
FIGURE 52 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025) 627
FIGURE 53 NIPPON SHINYAKU, CO. LTD.: COMPANY SNAPSHOT (2025) 632
FIGURE 54 NOVO NORDISK A/S: COMPANY SNAPSHOT (2025) 635
FIGURE 55 ARROWHEAD PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025) 637
FIGURE 56 SANOFI: COMPANY SNAPSHOT (2025) 641
FIGURE 57 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 644
FIGURE 58 MERCK KGAA: COMPANY SNAPSHOT (2025) 649
FIGURE 59 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 655
FIGURE 60 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025) 662
FIGURE 61 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 666
FIGURE 62 LGC LIMITED: COMPANY SNAPSHOT (2025) 670
FIGURE 63 TWIST BIOSCIENCE: COMPANY SNAPSHOT (2025) 675
FIGURE 64 GENSCRIPT: COMPANY SNAPSHOT (2025) 678
FIGURE 65 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2025) 682
FIGURE 66 KANEKA CORPORATION: COMPANY SNAPSHOT (2025) 689
FIGURE 67 AZENTA US INC.: COMPANY SNAPSHOT (2025) 693
FIGURE 68 REVVITY: COMPANY SNAPSHOT (2025) 701
FIGURE 69 REPROCELL INC.: COMPANY SNAPSHOT (2025) 711
FIGURE 70 OLIGONUCLEOTIDE SYNTHESIS MARKET: RESEARCH DESIGN 716
FIGURE 71 OLIGONUCLEOTIDE SYNTHESIS MARKET: BREAKDOWN OF PRIMARIES 719
FIGURE 72 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET ESTIMATION, 2025 720
FIGURE 73 OLIGONUCLEOTIDE-BASED DRUGS MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025) 721
FIGURE 74 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025) 722
FIGURE 75 OLIGONUCLEOTIDE SYNTHESIS MARKET: INSIGHTS FROM PRIMARIES 723
FIGURE 76 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 724
FIGURE 77 OLIGONUCLEOTIDE-BASED DRUGS MARKET: CAGR PROJECTIONS 726
FIGURE 78 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGOS MARKET: CAGR PROJECTIONS 727
FIGURE 79 OLIGONUCLEOTIDE SYNTHESIS MARKET: DATA TRIANGULATION 729
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們